Ross S L, Martin F, Simonet L, Jacobsen F, Deshpande R, Vassar R, Bennett B, Luo Y, Wooden S, Hu S, Citron M, Burgess T L
Department of Mammalian Cell Molecular Biology, Amgen Inc., Thousand Oaks, California 91320-1789, USA.
J Biol Chem. 1998 Jun 19;273(25):15309-12. doi: 10.1074/jbc.273.25.15309.
Amyloid peptides of 39-43 amino acids (Abeta) are the major constituents of amyloid plaques present in the brains of Alzheimer's (AD) patients. Proteolytic processing of the amyloid precursor protein (APP) by the yet unidentified beta- and gamma-secretases leads to the generation of the amyloidogenic Abeta peptides. Recent data suggest that all of the known mutations leading to early onset familial AD alter the processing of APP such that increased amounts of the 42-amino acid form of Abeta are generated by a gamma-secretase activity. Identification of the beta- and/or gamma-secretases is a major goal of current AD research, as they are prime targets for therapeutic intervention in AD. It has been suggested that the sterol regulatory element-binding protein site 2 protease (S2P) may be identical to the long sought gamma-secretase. We have directly tested this hypothesis using over-expression of the S2P cDNA in cells expressing APP and by characterizing APP processing in mutant Chinese hamster ovary cells that are deficient in S2P activity and expression. The data demonstrate that S2P does not play an essential role in the generation or secretion of Abeta peptides from cells, thus it is unlikely to be a gamma-secretase.
39至43个氨基酸的淀粉样肽(Aβ)是阿尔茨海默病(AD)患者大脑中淀粉样斑块的主要成分。淀粉样前体蛋白(APP)经尚未明确的β-和γ-分泌酶进行蛋白水解加工后,会产生具有淀粉样变的Aβ肽。最近的数据表明,所有导致早发性家族性AD的已知突变都会改变APP的加工过程,从而通过γ-分泌酶活性产生更多的42个氨基酸形式的Aβ。鉴定β-和/或γ-分泌酶是当前AD研究的主要目标,因为它们是AD治疗干预的主要靶点。有人提出,固醇调节元件结合蛋白位点2蛋白酶(S2P)可能与长期寻找的γ-分泌酶相同。我们通过在表达APP的细胞中过表达S2P cDNA,并通过表征缺乏S2P活性和表达的突变中国仓鼠卵巢细胞中的APP加工过程,直接验证了这一假设。数据表明,S2P在细胞产生或分泌Aβ肽的过程中不发挥重要作用,因此它不太可能是γ-分泌酶。